CEO to present with London Stock Exchange Head of Primary Markets at an event in Dallas, Texas
Bob Rauker to discuss accessing alternative sources of capital and his experience of listing a Company on the Alternative Investment Market (AIM)
LONDON, U.K. AND PLANO, TX, U.S. (1 November 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that CEO Robert “Bob” Rauker will be presenting alongside Chris Mayo, Head of Primary Markets (Americas), London Stock Exchange, at The Pulse Healthcare Innovation Breakfast event taking place in Dallas, Texas, USA, tomorrow.
The hybrid event, which is also supported by Department for International Trade (DIT), is designed to highlight how US-based companies are taking advantage of lower-cost execution and maintenance of a UK listing. The speakers will also discuss the high-quality investor base for smaller companies and the ongoing access to capital in London which has proven attractive to emerging US growth companies. At the event, Bob Rauker will explain the benefits of Belluscura’s London IPO and take Q&A with Rachel Carroll, President & Managing Partner of Edison Group, a global independent equity research, and investor relations firm.
Health Wildcatters, an organization that provides investment and key resources to support healthcare entrepreneurs, is hosting the in-person event on Tuesday the 2nd of November at 07:30 am–09:00 am CT. Those unable to be present are encouraged to attend a virtual meeting to be held via Zoom between the hours of 08:00 am–09:00 am CT on the same day.
Interested parties can register for the event, below:
A link to the Wildcatters website with the presentation information: https://www.healthwildcatters.com/
The event is being recorded and will be available on the Health WildCatters YouTube channel: https://www.youtube.com/c/HealthWildcattersDallas/videos
Chris Mayo will briefly set the scene as to why much smaller US emerging growth companies are looking to the London Stock Exchange after an introduction by Hubert Zajicek, MD, MBA, and Geraldine SCHOTT, Ph.D. of the Department for International Trade (DIT).
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
For further information please contact:
|Robert Rauker, Chief Executive Officer||via Walbrook PR|
|Anthony Dyer, Chief Financial Officer|
|SPARK Advisory Partners Limited (NOMAD)||Tel: +44 (0)20 3368 3550|
|Dowgate Capital Limited (Broker)||Tel: +44 (0)20 3903 7715|
|James Serjeant / Nicholas Chambers|
|Walbrook PR Ltd (Media & Investor Relations)||Tel: +44 (0)20 7933 8780 or email@example.com|
|Paul McManus / Sam Allen||Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258|
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers, and insurance organizations.